COCH (Envoy Medical) EBIT: $-22.01 Mil (TTM As of Mar. 2026)

What is Envoy Medical EBIT?

Envoy Medical COCH +15.91% 24 EBIT is $-22.01 Mil as of Mar. 2026. GuruFocus rates COCH with a GF Score™ of 24/100 and a GF Value™ of $1.14 (Possible Value Trap). The stock has 6 warning signs investors should review.

Envoy Medical's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-4.35 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-22.01 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Envoy Medical's annualized ROC % for the quarter that ended in Mar. 2026 was -759.11%. Envoy Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -931.69%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Envoy Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -68.10%.

Envoy Medical (NAS:COCH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Envoy Medical's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-23.836 * ( 1 - 0% )	/	( (3.282	+	2.998)	/ 2 )
=	-23.836	/	3.14
=	-759.11 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.558	-	10.559	-	( 3.739	-	max(0, 11.562	-	6.279	+	3.739	))
=	3.282

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	29.822	-	11.353	-	( 25.251	-	max(0, 12.211	-	27.682	+	25.251	))
=	2.998

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Envoy Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-17.404	/	( ( (1.921 + max(-8.867, 0))	+	(1.815 + max(-9.619, 0)) )	/	2 )
=	-17.404	/	( ( 1.921	+	1.815 )	/	2 )
=	-17.404	/	1.868
=	-931.69 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.034	+	1.546	+	0.941)	-	(10.559	+	0	+	0.829)
=	-8.867

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.031	+	1.49	+	0.893)	-	(11.353	+	0	+	0.68)
=	-9.619

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Envoy Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-22.014	/	32.326
	=	-68.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Envoy Medical EBIT Related Terms

Envoy Medical EBIT Historical Data

* Premium members only.

The historical data trend for Envoy Medical's EBIT can be seen below:

Envoy Medical EBIT Chart

Envoy Medical Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

-6.87

-8.71

-29.92

-19.98

-22.17

Envoy Medical Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial												-4.50	-5.07	-6.01	-6.59	-4.35

COCH vs ELUT, SRTS, BDMD: EBIT Comparison

For the Medical Devices subindustry, Envoy Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Envoy Medical EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Envoy Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Envoy Medical's EV-to-EBIT falls into.

Save Embed

24GF Score

Envoy Medical Inc COCH

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Envoy Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.01 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-22.01 Mil mean?

Envoy Medical (COCH) has a EBIT of $-22.01 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Envoy Medical.

Is Envoy Medical's EBIT too high?

Envoy Medical's current EBIT is $-22.01 Mil. Overall, Envoy Medical has a GF Score™ of 24/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Envoy Medical's EBIT compare to ELUT and SRTS?

Envoy Medical's EBIT of $-22.01 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Devices & Instruments company?

A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Envoy Medical. Envoy Medical's current EBIT is $-22.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Envoy Medical stock overvalued right now?

Based on GuruFocus' analysis, Envoy Medical (COCH) is currently considered Possible Value Trap. The stock's GF Value™ is $1.14, compared to a current price of $0.74 — trading 35.4% below its estimated fair value. The current EBIT is $-22.01 Mil. Envoy Medical's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Envoy Medical (COCH), the current EBIT is $-22.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Envoy Medical (COCH) Overvalued in 2026?

Based on GuruFocus' analysis, Envoy Medical stock appears to be undervalued. The current stock price of $0.74 is trading 35.4% below its estimated GF Value™ of $1.14. GuruFocus considers Envoy Medical to be Possible Value Trap.

Key valuation signals for COCH:

EBIT: $-22.01 Mil
GF Value™: $1.14 vs. price of $0.74 (35.4% below fair value)
GF Score™: 24/100 with 6 warning signs

No single metric tells the full story. See the COCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Envoy Medical Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ELUT SRTS BDMD POSC ARAY PAVM TELA XTNT NSPR MYO ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Address 4875 White Bear Parkway, White Bear Lake, MN, USA, 55110

Website https://www.envoymedical.com

Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.

24GF Score

Get the complete analysis for COCH

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.74

Price

$1.14

GF Value

View COCH Analysis

See EBIT data for all stocks →